



Press Release December 2015

Index

<u>Section</u>	<u>Page</u>
Section I. Risk rating	3
Section II. Revenues, EBITDA and Net Profit	3
Section III. Highlights	4
Section IV. Medical Facilities Investment Plan	4
Section V. Financial Results Summary	5
Section VI. Balance Sheet Analysis	7
Section VII. EBITDA Composition by Business Unit	10
Section VIII. Capex Composition	11
Section IX. Financial Highlights by Business Unit	12
Section X. Stock Market Information	18

Executive summary

Section I. Risk rating

Banmédica S.A. stock and bond risk ratings published by Fitch Rating and ICR are the following:

Stocks	Level 3
Bonds	AA-

Source: Credit Analysis Fitch Ratings- and ICR.

The stock and bond risk ratings are based on its strong credit profile due to the positive forecast for the private health industry in Chile and its strong presence in the Hospitals. Banmédica is a well-known brand in the industry properly diversified with a robust presence in Colombia and Perú.

Section II. Revenues, EBITDA and Net Profit

Operating revenues increased 25,36% reaching Ch\$ 1.328.307 million for 2015. This growth is mainly explained by:

- Higher operating revenues from Empremédica in Perú, mainly explained by adding “Pacífico Entidad Prestadora de Salud” and its subsidiaries.
- Higher operating revenues in Vidaintegra due to a new medical center and the increase in medical services.
- Higher operating revenues from Chilean Hospitals explained by a higher inpatient and outpatient activity.
- Higher operating revenues from the Isapre Area by the increase of its beneficiaries in 4,9% and in the average premium.

Company EBITDA increased 13,9% to Ch\$ 120.207 million and its net profit reached Ch\$ 45.767 million (-4,87%). EBITDA growth is explained by an increment in the Isapre Business and in Empremédica (Perú) by adding Pacífico EPS and its subsidiaries.

Section III. Highlights

- On December 30, 2014, Banmédica signed an agreement with the Peruvian company “El Pacífico Peruano Suiza Compañía de Seguros y Reaseguros”. This alliance will allow Empremédica to become a major player in the healthcare market in Perú.
- On July 27th 2015 Empresas Banmédica issued a long term bond in the market for the equivalent of UF2.200.000.

Section IV. Medical Facilities Investment Plan

In the year 2015, capex accounted Ch\$ 67.745 million equivalent to 2,66x depreciation.

Higher investments on fixed assets were allocated in Clínica Dávila (Ch\$ 20.033), Empremédica (Perú) (Ch\$ 17.214), Colmédica (Colombia) (Ch\$ 10.310), Clínica Santa María (Ch\$ 8.845), Clínica Vespucio (Ch\$ 5.173) and others (Ch\$ 6.170).

Section V. Financial Results Summary



	Dec.2015	Dec. 2014	Change
Revenues (Millions of Ch\$)	1.328.307	1.059.582	268.726
Ebitda (Millions of Ch\$)	120.207	105.536	14.670
Ebitda Margin (%)	9,05%	9,96%	-0,91%
Net Profit (Millions of Ch\$)	45.767	48.108	(2.341)
Net Margin (%)	3,45%	4,54%	-1,09%
Occupancy Rate (Hospitals)	75,60%	76,30%	-0,70%
Physician Consultations (Number)	4.362.742	4.193.970	168.772
Number of Insurance	1.677.266	897.855	779.411

*: Isapre Banmédica and Vida Tres December 2015-2014
Colmédica September 2015 y December 2014
Aliansalud Jun 2015 y December 2014.
Empremédica Pacifico EPS November 2015

Net Income attributable to shareholders reached Ch\$ 45.767 million (Ch\$ 56,88 per share), a decrease of 4,87% when compare to December 2014.

The main variation in net profit related to the same period of the last year, was caused by the income tax of Chilean subsidiaries, due to the tax reform occurred in September 2014, under the new tax system “partially integrated”, because it presents differences between assets and liabilities by deferred tax. Due to a gradual increase of the corporate income tax rate, where last year (2014) it was recognized like retained earnings (financial equity), while during this year (2015) the effect must be recognized as financial result of the period.

Empresas Banmédica						
Financial Highlights (Ch \$ Millions)	4Q 2015	4Q 2015	Change	Dec.2015	Dec. 2014	Change
Revenues	338.877	265.270	73.608	1.328.307	1.059.582	268.726
Cost of Sales	(272.338)	(200.573)	(71.765)	(1.063.482)	(828.238)	(235.244)
Gross Income	66.540	64.697	1.843	264.826	231.344	33.482
Gross Margin (%)	19,64%	24,39%	-4,75%	19,94%	21,83%	-1,90%
SG & A Expenses	(43.528)	(45.403)	1.874	(174.253)	(150.208)	(24.045)
Non Operating Result	(11.080)	(8.672)	(2.407)	(44.805)	(33.027)	(11.778)
Net Profit	11.932	10.622	1.310	45.767	48.108	(2.341)
Net Margin (%)	3,52%	4,00%	-0,48%	3,45%	4,54%	-1,09%
Ebitda	31.102	25.562	5.540	120.207	105.536	14.670
Ebitda Margin (%)	9,18%	9,64%	-0,46%	9,05%	9,96%	-0,91%



Section VI. Balance Sheet Analysis

Statement on Financial Position (Ch\$ Millions)		
	Dec.2015	Dec. 2014
Current Assets	322.300	241.807
Fixed Assets	397.037	329.254
Other Assets	315.204	173.796
Total Assets	1.034.542	744.858
Current Liabilities	389.948	319.374
Long Term Liabilities	317.120	215.772
Minoritary Interest	67.136	14.026
Equity	260.337	195.687
Equity and Liabilities	1.034.542	744.858
Cash and Cash Equivalents	61.522	32.513
Financial Debt	297.997	210.129
Net Financial Debt	236.475	177.616

The change in total assets between December 2015 and December 2014 was explained by:

Current Assets:

Increase in cash and cash equivalents in Empremédica due to the consolidation with Pacífico EPS, on investments in financial instruments (mutual funds) and higher collections from VidalIntegra and Colmédica.

Increase in accounts receivables in Empremédica due to the financial statement consolidation with Pacífico EPS and increase in accounts receivables of Clínica Dávila.

Fixed assets:

Increase in Intangible assets in Empremédica due to the financial statement consolidation with Pacífico EPS (brands, licenses and client relationship). Also participation contract with Pacífico Asistencia Médica (AMED)

Besides there is an increase in PP&E due to investments in Clínica Dávila and Clínica Santa María.

Other assets:

Increase in Goodwill and other assets in Empremédica due to the consolidation with Pacífico EPS.

Deferred tax in Colmédica due to a higher tax rate.

The change in Equity and Liabilities between December 2015 and December 2014 was explained by:

Current Liabilities:

Increase in financial debt in Clínica Dávila and in Empremédica due to the consolidation with Pacífico EPS

Increase in accounts payable in Empremédica due to the consolidation with Pacífico EPS.

Long-term Liabilities:

Increase in financial debt in Banmédica associated with the new issued bond.

Shareholders' Equity:

Shareholders Equity (Ch\$ million)	Quarter ended Dec 2015		Change %
	dec-2015	dec-2014	Dec.15-Dec.14
Capital	32.332	32.332	0,0%
Reserves	28.080	(8.202)	-2405,6%
Retained earnings:			
Retained earnings prior periods	167.888	137.882	12,6%
Income for the period	45.767	48.108	82,7%
Provision for mandatory dividend	(13.730)	(14.433)	80,1%
Equity attributable to shareholders	260.337	195.687	31,7%
Non-controlling interest	67.136	14.026	391,3%
Total Equity	327.473	209.713	55,0%
ROE*	20%	25%	-4,4%

(*) Annualized Net Profit attributable to shareholders / Average equity attributable to shareholders.

Shareholders' equity reached Ch\$260.337 million for 2015. ROE for the period was 20%.



Financial position and financial debt changes.

RATIOS	Dec.2015	Dec.2014
Indebtedness Ratio	2,72x	2,73x
Financial Indebtedness Ratio	0,91x	1,00x


The indebtedness ratio was 2,72 for December 2015, less compared to December 2014 explained by an increase in Equity associated to other reserves.

Financial expenses coverage decreased to 7,75 as of December 2015 explained by an increment in the financial expenses related to the increase of debt intended to investments and the addition of Empremédica.

Section VII.- EBITDA Composition by Business



Section VIII.- Capex Composition



Capex highlights:

New investment projects in Health Providers, mainly in Clínica Dávila, Colmédica (Colombia), Clínica Santa María, Empremédica (Perú) and Medium Size Hospitals.

Section IX.- Financial Highlights by Business Unit


Isapres results

Isapres						
Financial Highlights (Ch \$ Millions)	4Q 2015	4Q 2014	Change	Dec.2015	Dec. 2014	Change
Revenues	145.503	133.091	12.412	561.990	516.229	45.761
Cost of Sales	(126.555)	(119.562)	(6.994)	(488.412)	(454.007)	(34.406)
Gross Income	18.948	13.529	5.418	73.578	62.222	11.355
Gross Margin (%)	13,02%	10,17%	2,86%	13,09%	12,05%	1,04%
SG & A expenses	(15.828)	(13.066)	(2.761)	(60.256)	(51.481)	(8.775)
Non Operating Result	1.004	3.004	(2.000)	3.211	8.092	(4.882)
Net Income	4.124	3.467	657	16.532	18.834	(2.301)
Net Margin (%)	2,83%	2,61%	0,23%	2,94%	3,65%	-0,71%
Ebitda	3.572	913	2.660	15.060	12.389	2.672
Ebitda Margin (%)	2,46%	0,69%	1,77%	2,68%	2,40%	0,28%

The positive variation in the gross income is explained by a higher revenues due to an increase in the beneficiaries, increase in the average premium and a lower cost of sales due to less claims in outpatients.

SG&A expenses increase is explained by higher litigation cost.

The lower net income is mainly explained by the new income tax regulation.




Source: Superintendencia de Salud.

Hospitals results:

Hospitals						
Financial Highlights (Ch \$ Millions)	4Q 2015	4Q 2014	Change	Dec.2015	Dec.2014	Change
Revenues	95.815	79.930	15.884	359.401	328.516	30.885
Cost of Sales	(72.988)	(56.714)	(16.274)	(273.990)	(244.609)	(29.381)
Gross Income	22.827	23.217	(390)	85.411	83.908	1.503
Gross Margin (%)	23,82%	29,05%	-5,22%	23,76%	25,54%	-1,78%
SG & A expenses	(12.661)	(13.316)	655	(48.791)	(45.160)	(3.631)
Non Operating Result	(3.792)	(3.785)	(7)	(14.104)	(14.343)	239
Net Income	6.374	6.116	259	22.516	24.405	(1.889)
Net Margin (%)	6,65%	7,65%	-1,00%	6,26%	7,43%	-1,16%
Ebitda	14.204	13.812	392	52.763	54.088	(1.325)
Ebitda Margin (%)	14,82%	17,28%	-2,46%	14,68%	16,46%	-1,78%

The net income presented in the Clinical Area decrease 7.74% compared to the prior period due to higher operating costs associated with medical fees, wages and materials.



Source: Clínicas de Chile A.G

Outpatient results:

Outpatient network						
Financial Highlights (Ch \$ Millions)	4Q 2015	4Q 2014	Change	Dec.2015	Dec. 2014	Change
Revenues	17.161	14.995	2.166	66.044	57.672	8.372
Cost of Sales	(14.401)	(13.342)	(1.059)	(55.700)	(48.968)	(6.733)
Gross Income	2.760	1.653	1.107	10.344	8.704	1.639
Gross Margin (%)	16,08%	11,02%	5,06%	15,66%	15,09%	0,57%
SG & A expenses	(1.325)	126	(1.451)	(5.248)	(3.901)	(1.347)
Non Operating Result	(503)	(779)	276	(1.842)	(2.037)	195
Net Income	931	999	(68)	3.254	2.766	487
Net Margin (%)	5,43%	6,66%	-1,24%	4,93%	4,80%	0,13%
Ebitda	2.341	2.713	(372)	8.741	8.407	335
Ebitda Margin (%)	13,64%	18,09%	-4,45%	13,24%	14,58%	-1,34%

Best results in Vidaintegra are explained by an increase in its sales due to the opening of a new medical center and the remodeling of other two. This meant higher occupancy and services offered

Rescue Services results:

Rescue Services						
Financial Highlights (Ch \$ Millions)	4Q 2015	4Q 2014	Change	Dec.2015	Dec.2014	Change
Revenues	7.478	7.294	184	29.753	25.703	4.050
Cost of Sales	(4.163)	(3.840)	(323)	(16.752)	(13.386)	(3.366)
Gross Income	3.315	3.454	(139)	13.001	12.317	684
Gross Margin (%)	44,33%	47,35%	-3,02%	43,70%	47,92%	-4,22%
SG & A expenses	(2.576)	(2.910)	334	(10.799)	(10.621)	(178)
Non Operating Result	(147)	(101)	(47)	(467)	73	(540)
Net Income	592	443	149	1.735	1.769	(34)
Net Margin (%)	7,91%	6,07%	1,84%	5,83%	6,88%	-1,05%
Ebitda	886	643	244	2.792	2.197	595
Ebitda Margin (%)	11,85%	8,81%	3,04%	9,39%	8,55%	0,84%

Growth in Ebitda and Ebitda Margin are explained by a higher operating revenue due to the merge with Home Medical Clinic, company focused on providing clinical services at home.

Colmédica results:

Colmédica Colombia						
Financial Highlights (Ch \$ Millions)	4Q 2015	4Q 2014	Change	Dec.2015	Dec. 2014	Change
Revenues	43.279	53.370	(10.091)	191.594	219.263	(27.669)
Cost of Sales	(31.105)	(37.440)	6.335	(144.681)	(167.361)	22.680
Gross Income	12.174	15.930	(3.756)	46.913	51.902	(4.988)
Gross Margin (%)	28,13%	29,85%	-1,72%	24,49%	23,67%	0,81%
SG & A expenses	(7.359)	(11.183)	3.824	(29.535)	(34.590)	5.055
Non Operating Result	(1.428)	(1.355)	(73)	(6.349)	(5.130)	(1.219)
Net Income	3.386	3.391	(5)	11.029	12.181	(1.152)
Net Margin (%)	7,82%	6,35%	1,47%	5,76%	5,56%	0,20%
Ebitda	5.481	5.398	83	18.641	18.576	65
Ebitda Margin (%)	12,66%	10,11%	2,55%	9,73%	8,47%	1,26%

The lower net income for year 2015 is due to the higher depreciation of the Colombian peso against the Chilean peso, generating a negative exchange rate effect. In local currency, the revenue and net income are higher than previous year.

Results for Colombian Hospitals

Colombia Hospitals						
Financial Highlights (Ch \$ Millions)	4Q 2015	4Q 2014	Change	Dec. 2015	Dec. 2014	Change
Revenues	16.471	16.892	(420)	68.870	70.785	(1.915)
Cost of Sales	(11.302)	(10.867)	(435)	(44.773)	(46.120)	1.346
Gross Income	5.169	6.025	(855)	24.096	24.665	(569)
Gross Margin (%)	31,38%	35,67%	-4,28%	34,99%	34,85%	0,14%
SG & A expenses	(3.181)	(3.920)	739	(14.751)	(17.396)	2.644
Non Operating Result	(9)	(835)	827	(3.717)	(4.349)	632
Net Income	1.979	1.269	710	5.628	2.920	2.708
Net Margin (%)	12,02%	7,51%	4,50%	8,17%	4,13%	4,05%
Ebitda	3.078	4.466	(1.389)	12.372	12.233	140
Ebitda Margin (%)	18,68%	26,44%	-7,76%	17,96%	17,28%	0,68%

The higher net profit is due to a decrease in administrative expenses. In local currency, the revenue and net income are higher than previous year.

Empremédica Results:


Empremédica						
Financial Highlights (Ch \$ Millions)	4Q 2015	4Q 2014	Change	Dec.2015	Dec. 2014	Change
Revenues	129.237	18.672	110.565	259.792	36.066	223.726
Cost of Sales	(107.726)	(12.337)	(95.389)	(217.126)	(23.814)	(193.312)
Gross Income	21.511	6.335	15.176	42.667	12.252	30.414
Gross Margin (%)	16,64%	33,93%	-17,28%	16,42%	33,97%	-17,55%
SG & A expenses	(13.621)	(1.335)	(12.286)	(25.986)	(3.317)	(22.668)
Non Operating Result	(8.136)	(1.696)	(6.440)	(15.443)	(3.440)	(12.003)
Net Income	(247)	3.304	(3.550)	1.238	5.495	(4.257)
Net Margin (%)	-0,19%	17,69%	-17,88%	0,48%	15,24%	-14,76%
Ebitda	11.482	5.765	5.716	22.441	10.441	11.999
Ebitda Margin (%)	8,88%	30,88%	-21,99%	8,64%	28,95%	-20,31%

Revenues, gross margin and ebitda are increased due to the consolidation of the financial statement of Pacífico EPS in Empremédica.

The non-operating result is lower due to Empremédica's financial debt with Banmédica.

The ebitda margin was affected by the inclusion of the insurance business that has low margin.

Section X.- Stock Market Information



Banmédica	
Closing Price 31/12/2015 (Ch\$ per share)	1.021,00